|Abnormal levels of some proteins in the blood may help predict the risk of Alzheimer's disease|
Xinhua News Agency, Beijing, June 26.
A new study conducted by American researchers found that the risk of Alzheimer's disease is related to abnormal levels of dozens of proteins in the blood, and this abnormality has begun to appear several years in advance
The new findings provide ideas for the development of preventive treatments for Alzheimer's disease
The Johns Hopkins-Bloomberg School of Public Health in the United States recently issued a communiqué stating that this new study uses blood samples collected and stored in a large-scale study in the United States that has lasted for decades
The researchers first analyzed the blood samples of 4,800 middle-aged and elderly subjects collected between 2011 and 2013, and measured the levels of nearly 5,000 proteins in these samples
It was found that the abnormal levels of 38 proteins in the blood samples were associated with an increased risk of Alzheimer's disease within 5 years after the subjects were drawn
The researchers analyzed the blood samples of 11,000 younger subjects collected between 1993 and 1995 and measured their protein levels
Combining the follow-up information of these subjects nearly 20 years later, the researchers found that abnormal levels of 16 of the 38 proteins previously identified had begun to appear about 20 years before the onset of Alzheimer's disease
In further statistical analysis, the researchers compared some of the identified proteins with the results of previous studies on Alzheimer's disease-related genes and found that a protein called SVEP1 is not only a marker of increased risk of Alzheimer's disease And it may be a factor in the disease
Related papers have been published in the British "Nature·Aging" magazine
The senior author of the paper and a professor at the Johns Hopkins-Bloomberg School of Public Health, Joseph Corrish, said that this is the most comprehensive analysis of its kind to date, revealing multiple types of Alzheimer’s disease.
Biological pathways show the potential for the development of therapeutics targeting these proteins in the future
Alzheimer's disease is a degenerative disease of the nervous system.
It is clinically characterized by memory impairment, aphasia, executive dysfunction, and personality and behavior changes.
Pathological features include β-amyloid protein deposition and Tau protein hyperphosphorylation.
The etiology So far it is not clear
Scientists generally believe that the best time to treat Alzheimer's disease is before the symptoms of dementia appear